SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, ladies and gentlemen, and welcome to the Protalix ...

With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...

Atara Biotherapeutics Inc ( (ATRA) ) has released its Q3 earnings. Here is a breakdown of the information Atara Biotherapeutics Inc presented ...

Funding to support clinical proof-of-concept for the lead program, VIPER-101 PHILADELPHIA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ...

Artiva Biotherapeutics, Inc. ( (ARTV) ) has released its Q3 earnings. Here is a breakdown of the information Artiva Biotherapeutics, Inc.

Research that was carried out by Baylor College of Medicine and Texas Children's Hospital doctors has led to the U.S. Food ...

Calidi Biotherapeutics (NYSE American: CLDI) has announced plans to sell shares of its common stock and/or pre-funded warrants in a <a target ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

Collaboration Revenue - Collaboration revenue was $1.1 million for the quarter ended September 30, 2024, compared to $2.5 ...

Detailed price information for Sonnet Biot Inc (SONN-Q) from The Globe and Mail including charting and trades.

Shares of Calidi Biotherapeutics surged after the immuno-oncology company reported quarterly results but lost some of their gains after it announced a proposed stock offering. The stock gained 60% to ...